These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [Relations between IL-2-330 polymorphisms and the outcome of hepatitis B and/or hepatitis C virus infection]. Author: Gao QJ, Liu DW, Zhang SY, Wu LH, Jia M. Journal: Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Sep; 31(9):1041-5. PubMed ID: 21162873. Abstract: OBJECTIVE: To study the relationship between polymorphisms in interleukin-2 gene at position -330 (IL-2-330) and the clinical outcome of hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection. METHODS: 277 subjects were recruited including 79 chronic HCV co-HBV infection, 55 chronic HCV infection, 69 chronic HBV infection and 74 controls. Single nucleotide polymorphisms of IL-2-330 was investigated by restricted fragment long polymorphism-PCR (RFLP-PCR). Hepatocellular injury, as revealed by alanine aminotransferase (ALT) was detected by Beckman LX-20 analyzer. The presence of hepatitis C viral particles in serum was determined by RT-nPCR. RESULTS: (1) IL-2-330 polymorphisms showed close association with persistent HBV and/or HCV infection. IL-2-330 TT was associated with an increased risk, but IL-2-330 GG with a reduced risk of persistent HBV and/or HCV infection (χ(2) = 14.24, P = 0.03) with ORs (95%CI) as 7.14 (2.13 - 23.81), 3.46 (1.17 - 10.02) and 2.93 (1.15 - 7.46) respectively. However, IL-2-330 TT/GG did not significantly differ between patients with HBV and/or HCV infection (χ(2) = 2.09, P = 0.72). IL-2-330 T allele was associated with an increased risk, but the -330G allele was associated with a reduced risk of chronic HBV/HCV infection (χ(2) = 12.33, P = 0.01), with ORs (95%CI) as 2.26 (1.39 - 3.69), 1.82(1.09 - 3.03) and 1.73 (1.10-2.73) respectively. (2) IL-2-330 polymorphisms showed significant association with the outcome of HBV and HCV infection (χ(2) = 13.52, P = 0.04). IL-2-330 TT was associated with an increased risk, but -330 GG with a reduced risk of mild CH, moderate/severe CH, and cirrhosis. The ORs (95%CI) appeared to be 3.33 (1.75 - 6.32), 3.31 (1.75 - 6.26), 11.23 (3.09 - 40.76) respectively. IL-2-330 T allele was associated with an increased risk, but the -330 G allele was associated with a reduced risk of mild CH, moderate/severe CH and cirrhosis (χ(2) = 12.32, P = 0.01), with ORs as 1.86 (1.32 - 2.63), 1.71 (1.27 - 2.31) and 2.77 (1.57 - 4.89) respectively. (3) The polymorphisms of IL-2-330 showed no association with HCV RNA replication (χ(2) = 0.83, P = 0.66; χ(2) = 0.20, P = 0.66). The polymorphisms of IL-2-330 were not significantly associated with abnormal ALT (χ(2) = 1.10, P = 0.58; χ(2) = 0.08, P = 0.78). CONCLUSION: These results suggested that IL-2-330 TT/T was associated with an increased risk, but IL-2-330 GG/G was associated with reduced risk of persistent HBV and/or HCV infection, and with the development of mild CH, moderated/severe CH, and cirrhosis.[Abstract] [Full Text] [Related] [New Search]